- Home
- NUVL vs BBWI Comparison
NUVL vs BBWI Comparison
Compare NUVL & BBWI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- BBWI
- Stock Information
- Founded
- NUVL 2017
- BBWI 1963
- Country
- NUVL United States
- BBWI United States
- Employees
- NUVL N/A
- BBWI N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- BBWI Clothing/Shoe/Accessory Stores
- Sector
- NUVL Health Care
- BBWI Consumer Discretionary
- Exchange
- NUVL Nasdaq
- BBWI Nasdaq
- Market Cap
- NUVL 6.5B
- BBWI 5.3B
- IPO Year
- NUVL 2021
- BBWI N/A
- Fundamental
- Price
- NUVL $104.59
- BBWI $24.41
- Analyst Decision
- NUVL Strong Buy
- BBWI Buy
- Analyst Count
- NUVL 11
- BBWI 17
- Target Price
- NUVL $121.45
- BBWI $38.28
- AVG Volume (30 Days)
- NUVL 498.8K
- BBWI 5.7M
- Earning Date
- NUVL 11-10-2025
- BBWI 11-24-2025
- Dividend Yield
- NUVL N/A
- BBWI 3.07%
- EPS Growth
- NUVL N/A
- BBWI N/A
- EPS
- NUVL N/A
- BBWI 3.38
- Revenue
- NUVL N/A
- BBWI $7,371,000,000.00
- Revenue This Year
- NUVL N/A
- BBWI $4.22
- Revenue Next Year
- NUVL N/A
- BBWI $2.93
- P/E Ratio
- NUVL N/A
- BBWI $7.36
- Revenue Growth
- NUVL N/A
- BBWI N/A
- 52 Week Low
- NUVL $55.54
- BBWI $24.81
- 52 Week High
- NUVL $103.69
- BBWI $41.87
- Technical
- Relative Strength Index (RSI)
- NUVL 71.49
- BBWI 37.05
- Support Level
- NUVL $90.00
- BBWI $26.03
- Resistance Level
- NUVL $99.94
- BBWI $27.40
- Average True Range (ATR)
- NUVL 4.59
- BBWI 0.82
- MACD
- NUVL 1.10
- BBWI -0.06
- Stochastic Oscillator
- NUVL 100.00
- BBWI 4.17
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About BBWI Bath & Body Works Inc.
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with just 5% of sales from international markets in fiscal 2024. For fiscal 2024, 76% of sales stemmed from the brick-and-mortar network (which was composed of more than 1,800 retail stores), similar to 2023 levels, as consumer shopping patterns remained to normal. Future growth is expected from store upgrades, digital and international channels, as well as adjacent category expansions like hair and laundry.